Peter de Haan
Fondatore presso Amarna Therapeutics BV
Posizioni attive di Peter de Haan
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Barranco Resources NL
 Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Direttore/Membro del Consiglio | - | - |
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Direttore Tecnico/Scientifico/R&S | 01/01/2009 | - |
| Fondatore | 01/01/2008 | - |
Storia della carriera di Peter de Haan
Statistiche
Distribuzione geografica
| Australia | 2 |
| Paesi Bassi | 2 |
Posizioni
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Settori
| Distribution Services | 2 |
| Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Barranco Resources NL
Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Distribution Services |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
- Borsa valori
- Insiders
- Peter de Haan
- Esperienza